GLAUKOS Corp·4/A

Jun 23, 7:22 PM ET

Torres Denice 4/A

4/A · GLAUKOS Corp · Filed Jun 23, 2026

Research Summary

AI-generated summary of this filing

Updated

GLAUKOS Director Denice Torres Receives Option Award (2,987)

What Happened Denice Torres, a director of GLAUKOS Corp (GKOS), was granted a derivative award on 2026-05-28 covering 2,987 shares (options) with an exercise price of $106.52. The Form 4A filed 2026-06-23 amends an earlier Form 4 to correct the exercise price (previously reported as $53.57). The grant was reported as an acquisition (code A) and vests in full on the one-year anniversary of the grant.

Key Details

  • Transaction date: 2026-05-28 (reported via amended Form 4 on 2026-06-23).
  • Award: 2,987 option rights; exercise price: $106.52 per share (corrected from $53.57).
  • Consideration reported at grant: $0 (typical for equity awards; this is not an open‑market purchase).
  • Vesting: Vests in full one year after grant date (per issuer’s Director Compensation Policy).
  • Ownership after transaction: Not specified in the information provided.
  • Filing status: Amended Form 4; original Form 4 (filed June 1) contained the incorrect exercise price — amendment improves accuracy but the report was filed after the transaction date.

Context This was a director compensation grant (routine for non-employee directors) rather than a market purchase or sale. As a derivative award, no shares were sold or bought immediately — Torres will have the right to exercise these options in the future at $106.52 per share if and when vested and exercised, which could dilute shares if exercised. The amendment corrected the strike price, improving transparency for investors; the filing was submitted after the transaction date.

Insider Transaction Report

Form 4/AAmended
Period: 2026-05-28
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-05-28+2,9872,987 total
    Exercise: $106.52From: 2027-05-28Exp: 2036-05-28Common Stock (2,987 underlying)
Footnotes (2)
  • [F1]This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
  • [F2]Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Signature
Diana Scherer, Attorney-in-Fact|2026-06-23

Documents

1 file
  • 4
    form4a-06232026_110610.xml